Home
Conference Highlights
View All Conference Highlights
Year in Review / Wrap-Ups
Wrap-Ups
Year in Review
Contact Us
Conference Highlights
American Society of Clinical Oncology (ASCO)
ASCO 2020 – Lung Cancer
ASCO 2020 – Lung Cancer
Impact of Immune-Related Adverse Events on Checkpoint Inhibitor Consolidation Therapy in Stage III NSCLC
ASCO 2020 – Lung Cancer
Immune-related adverse events did not affect the clinical benefit of consolidation checkpoint inhibitor therapy after chemoradiation in stage III non–small-cell lung cancer.
Read More ›
3-Year Follow-Up Data for Nivolumab Combined with Ipilimumab in Treatment-Naïve NSCLC: CheckMate-227
ASCO 2020 – Lung Cancer
After 3 years of follow-up, nivolumab combined with ipilimumab demonstrates sustained overall survival rates in treatment-naïve patients with advanced non–small-cell lung cancer.
Read More ›
CheckMate-9LA Evaluates Addition of Chemotherapy to NIVO + IPI in First-Line Advanced NSCLC
ASCO 2020 – Lung Cancer
The addition of 2 cycles of chemotherapy to the combination of nivolumab and ipilimumab results in superior overall survival in treatment-naïve patients with advanced non–small-cell lung cancer.
Read More ›
Immunotherapy Combined with Stereotactic Radiation in Early-Stage, Medically Inoperable NSCLC: Safety Analysis from I-SABR
ASCO 2020 – Lung Cancer
Stereotactic ablative radiotherapy combined with immunotherapy (I-SABR) is well-tolerated in patients with early-stage, medically inoperable, isolated-recurrence non–small-cell lung cancer without lymph node or distant metastasis.
Read More ›
Meta-analysis of Checkpoint Inhibitor Trials in Front-Line NSCLC
ASCO 2020 – Lung Cancer
Based on a meta-analysis of randomized trials in the first-line treatment of non–small-cell lung cancer, adding chemotherapy to immune checkpoint inhibitors (ICIs) improves response rates and progression-free survival in some patients compared with ICI monotherapy, but does not confer an overall survival benefit regardless of PD-L1 status.
Read More ›
Real-World Data for Nivolumab in Patients with Malignant Mesothelioma
ASCO 2020 – Lung Cancer
Standard treatment for patients with advanced malignant pleural mesothelioma is predominantly chemotherapy-based. Nivolumab may be effective in these patients based on a retrospective real-world data assessment.
Read More ›
Page 2 of 2
1
2
Conference Correspondent Coverage is Brought to You by the Publishers of:
Learn more about our family of publications.
View Our Publications
Supported through funding by
Home
Conference Highlights
View All Conference Highlights
Year in Review / Wrap-Ups
Wrap-Ups
Year in Review
Contact Us